New service – bi-specific antibodies!
Fusion Antibodies are proud to offer a new and unique service of generation of antibodies which are hybrids of two of your Therapeutic monoclonals.
With the recent press attention surrounding the first FDA approved bi-specific antibody; catumaxomab and the announcement of the Humanization of Fusion Therapeutics very own fsn1006 double-targeting antibody, there has never been a better time to combine the effects of your antibodies.
Fusion Antibodies have a long history of custom scFv and Fab fragment production and we are excited to offer this great new service to you.
